Zusammenfassung
Vor über 40 Jahren entdeckten Delay et al. (Delay et al. 1952) die antipsychotischen Eigenschaften von Chlorpromazin. Zwar vermochte Chlorpromazin die Schizophrenie nicht zu heilen, doch war seine Entdeckung ein bedeutender Durchbruch in der Therapie dieser schweren Krankheit — die Gabe von Chlorpromazin verhindert bei schizophrenen Patienten einige der am stärksten beeinträchtigenden Symptome, wie z. B. Halluzinationen und Wahnvorstellungen.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Literatur
Andersen PH (1988) Comparison of the pharmacological characteristics of [3H]raclopride and [3H]-SCH-23390 binding to dopamine receptors in vivo in mouse brain. Eur J Pharmacol 146: 113–120
Andersen PH, Braestrup C (1986) Evidence for different states of the dopamine D1 receptor: clozapine and fluperlapine may preferentially label an adenylate cyclase coupled state of the DI receptor. J Neurochem 47: 1822
Andersen PH, Gronvald FC (1986) Specific binding of [3H]-SCH-23390 to dopamine D1 receptors in vivo. Life Sci 38: 1507–1515 (Published erratum appears in Life Sci 19:1117)
Andersen PH, Gronvald FC, Aas Jansen J (1985) A comparison between dopamine stimulated adenylate cyclase and [3H]-SCH-23390 binding in rat striatum. Life Sci 37: 191
Andersen PH, Nielsen EB, Grynvald FC, Braestrup C (1986) Some atypical neuroleptics inhibit [3H]-SCH-23390 binding in vivo. Eur J Pharmacol 120: 143–144
Andersen PH, Gingrich JA, Bates MD, Dearry A, Falardeau P, Senogles SE, Caron MG (1990) Dopamine receptor subtypes: beyond the D1/D2 classification. TIPS 11: 231
Andersen PH, Grlnvald FC, Hohlweg R, Hansen LB, Guddal E, Braestrup C, Nielsen EB (1992) NNC-112, NNC-687 and NNC-756, new selective and highly potent dopamine D1 receptor antagonists. Eur J Pharmacol 21: 45–52
Apud JA, Masotto C, Ongini E, Racagni G (1985) Interaction of SCH-23390, a D1 selective antagonist with the anterior pituitary D2 receptors and prolactin secretin in the rat. Eur J Pharmacol 112: 187–193
Bouvier C, Salon JA, Johnson RA, Civelli O (1993) Dopaminergic activity measured in D1- and D2-transfected fibroblasts by silicon-microphysiometry. J Recept Res 13: 559–571
Boyson SJ, McGonigle DLP, Molinoff PB (1986) Quantitative autoradiographic localization of the D1 and D2 subtypes of dopamime receptors in rat brain. J Neurosci 6: 3177–3188
Carlsson A (1978) Does dopamine have a role in schizophrenia? Biol Psychiatry 13: 3–21
Christensen AV, Amt J, Hyttel J, Larsen JJ, Svendsen O (1984) Pharmacological effect of a specific dopamine D1 antagonist SCH-23390 in comparison with neuroleptics. Life Sci 34: 1529–1540
Civelli O, Bunzow JR, Grandy DK (1993) Molecular diversity of the dopamine receptors. Annu Rev Pharmacol Toxicol 32: 281–307
Creese I, Burt DR, Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192: 481–483
Dawson TM, Gehlert DR, McCabe RT, Barnett A, Wamsley JK (1986) D-1 dopamine receptors in the rat brain: a quantitative autoradiographic analysis. J Neurosci 6: 2352–2365
Dearry A, Gingrich JA, Falardeau P, Fremeau RT, Bates MD, Caron MG (1990) Molecular cloning and expression of the gene for a human D1 dopamine receptor. Nature 347: 72
Delay J, Deniker P, Harl J-M (1952) Traitment des etats d’excitation et d’agitation par une méthode médicamenteuse dérivée de l’hiberno-thérapie. Ann Med Psychol (Paris) 110: 267–273
Farde L, Wiesel F-A, Hall H, Halldin C, Sedvall G (1988) Central D2-dopamine receptor occupancy in schizophenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 145: 71
Farde L, Wiesel F-A, Nordström A-L, Sedvall G (1989) D1- and D2-dopamine receptor occupancy during treatment with conventional and atypcial neuroleptics. Psychopharmacology 99: 28
Fremeau RJ jr, Duncan GE, Fornaretto M-G et al. (1991) Localization of D1 dopamine receptor mRNA in brain support: a role in cognitive, affective and neuroendocrine aspects of dopaminergic transmission. Proc Natl Acad Sci USA 88: 3772–3776
Grandy DK, Zhang Y, Bouvier C et al. (1991) Multiple human D5 dopamine receptor genes: a functional receptor and two pseudo genes. Proc Natl Acad Sci USA 88: 9175
Hyttel J (1978) Effects of neuroleptics on [3H]-Haloperidol binding and [3I]-flupenticol binding and on adenylate cyclase in vitro. Life Sci 23: 551–556
Hyttel J (1983) SCH-23390–The first selective D1 antagonist. Eur J Pharmacol 91: 153–154
Iorio LC, Barnett A, Leits FH, Houser VP, Korduba CA (1983) SCH-23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems. J Pharmacol Exp Ther 226: 462–268
Kebabian JW, Caine DB (1979) Multiple receptors for dopamine. Nature 277: 93
Mahan LC, Burch RM, Monsma FJ, Sibley DR (1990) Expression of strital D1 dopamine receptors coupled to inositol phosphate production and calcium mobilization in Xenopus oocytes. Proc Natl Acad Sci USA 87: 2196
Meador-Woodruff JH, Mansour A, Grandy DK, Damask SP, Civelli O, Watson SJ jr (1992) Distribution of D5 dopamine receptor mRNA in rat brain. Neurosci Lett 145: 209–212
Meltzer HY (1988) New insights into schizophrenia through atypcial antipsychotic drugs. Neurophsychopharmacology 1: 193–196
Morelli M, Di Chiara G (1985) Catalepsy induced by SCH-23390 in rats. Eur J Pharmacol 117: 179
Nielsen EB, Andersen PH (1992) Dopamine receptor occupancy in vivo: behavioral correlates using NNC-112, NNC-687 and NNC-756, new selective dopamine D1 receptor antagonists. Eur J Pharmacol 219: 35–44
Nielsen EB, Jepsen SA (1985) Antagonism of the amphetamine cue by both classical and atypical antipsychotic drugs. Eur J Pharmacol 111: 167
O’Dowd BF (1993) Structures of dopamine receptors. J Neurochem 60: 804–816
Pedersen UB, Norby B, Jensen AA et al. (1995) Characteristics of stably expressed human D1a and 13 lb receptors: atypical behavior of the D1b receptor. Eur J Pharmacol (in press)
Seeman P, Lee T, Chan-Wong M, Wong K (1976) Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261: 717–719
Sunahara, RK, Niznik HB, Weiner DM et al. (1990a) Human dopamine D1 receptor encoded by an intronless gene on chromosome 5. Nature 347: 80
Sunahara RK, Guan H-C, O’Dowd BF et al. (1990b) Cloning of a gene for a human dopamine D5 receptor with higher affinity for dopamine than Di. Nature 350: 614
Tiberi M, Jarvie KR, Silvia C et al. (1991) Cloning, molecular characterization and chromosomal assignment of a gene encoding a second Di dopamine receptor subtype: differential expression pattern in rat brain compared with the Dia receptor. Proc Natl Acad Sci USA 88: 7491
Undie AS, Friedman E (1990) Stimulation of a D1 receptor enhances inositol phosphates formation in rat brain. J Pharmacol Exp Ther 253: 987
Weiner DM, Levey AI, Sunahara RK, Niznik HB, O’Dowd BF, Seeman P, Brann MR (1991) D1 and D2 dopamine receptor mRNA in rat brain. Proc Natl Acad Sci USA 88: 1859
Weinshank RL, Adham N, Macchi M, Olsen MA, Branchek TA, Hartig PR (1991) Molecular cloning and characterization of a high affinity dopamine receptor (D1O) and its pseudogene. J Biol Chem 266: 22427
Zhou Q-Y, Grandy DK, Thambi L et al. (1990) Cloning and expression of human and rat D1 dopamine receptors. Nature 347: 76
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Andersen, P.H. (1995). Dopaminrezeptoren und Schizophrenie: Bedeutung der D1- und D5-Rezeptoren. In: Gerlach, J. (eds) Schizophrenie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-79738-5_3
Download citation
DOI: https://doi.org/10.1007/978-3-642-79738-5_3
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-59243-3
Online ISBN: 978-3-642-79738-5
eBook Packages: Springer Book Archive